<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02104076</url>
  </required_header>
  <id_info>
    <org_study_id>10-014</org_study_id>
    <nct_id>NCT02104076</nct_id>
  </id_info>
  <brief_title>Evolution® Biliary Stent System-Fully Covered</brief_title>
  <official_title>Evaluation for the Effectiveness of Evolution® Biliary Stent System-Fully Covered</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cook Group Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cook Group Incorporated</source>
  <brief_summary>
    <textblock>
      The Evolution® Biliary Stent System-Fully Covered study is a clinical trial approved by the&#xD;
      US FDA to evaluate the effectiveness of the Evolution® Biliary Stent System-Fully Covered&#xD;
      when used in palliation of malignant neoplasms in the biliary tree.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">January 4, 2017</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients free from symptomatic recurrent of biliary obstruction requiring reintervention</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Serum Bilirubin ≤ 3.0 mg/dL</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Carcinomas/Neoplasms</condition>
  <arm_group>
    <arm_group_label>Evolution® Biliary Stent-Fully Covered</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Evolution® Biliary Stent-Fully Covered</intervention_name>
    <description>Implantation of the Evolution® Biliary Stent-Fully Covered in the common bile duct utilizing ERCP</description>
    <arm_group_label>Evolution® Biliary Stent-Fully Covered</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Inoperable malignant neoplasm causing biliary obstruction or stricture that requires a&#xD;
             fully covered metal stent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt; 18 years of age&#xD;
&#xD;
          -  Unwilling or unable to sign and date the informed consent&#xD;
&#xD;
          -  Unwilling or unable to comply with the follow-up schedule&#xD;
&#xD;
          -  Undergone or is planning to undergo brachytherapy with transpapillary or percutaneous&#xD;
             implantation of intracavitary radiation sources&#xD;
&#xD;
          -  Participating in another investigational drug or device study in which patient has not&#xD;
             completed the follow-up phase for the primary endpoint at least 30 days prior to&#xD;
             enrollment&#xD;
&#xD;
          -  Endoscopic procedures are contraindicated&#xD;
&#xD;
          -  Current anatomy upstream of intended stent placement compromising the flow of bile&#xD;
             from the liver such that stent placement may not alleviate the biliary obstruction&#xD;
             symptoms&#xD;
&#xD;
          -  Presence of a metal biliary stent&#xD;
&#xD;
          -  Presence of an esophageal or duodenal stent&#xD;
&#xD;
          -  Hypersensitivity/allergy or contraindication to any component of the stent, delivery&#xD;
             system, or medication required to complete the procedure,which in the investigator's&#xD;
             opinion cannot be adequately premedicated&#xD;
&#xD;
          -  Coagulopathy&#xD;
&#xD;
          -  Diffuse intrahepatic metastases that involves &gt; 10 % of the liver&#xD;
&#xD;
          -  Life expectancy of &lt; 3 months&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  Active alcohol or substance abuse issue&#xD;
&#xD;
          -  Jaundice secondary to a cause other than biliary duct obstruction&#xD;
&#xD;
          -  Additional endoscopic restrictions as specified in the Clinical Investigation Plan&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raj Shah, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marco Bruno, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medish Centrum</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borland-Groover Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908-0908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de 1'Université</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon Cedex 03</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital L'Archet 2</name>
      <address>
        <city>Nice Cedex 03</city>
        <zip>23079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medish Centrum</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>April 2, 2014</study_first_submitted>
  <study_first_submitted_qc>April 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2014</study_first_posted>
  <disposition_first_submitted>June 30, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>June 30, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">July 5, 2017</disposition_first_posted>
  <last_update_submitted>June 30, 2017</last_update_submitted>
  <last_update_submitted_qc>June 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bile Duct Obstructions</keyword>
  <keyword>Biliary Stases</keyword>
  <keyword>Biliary Tract</keyword>
  <keyword>Stents</keyword>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

